Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review

• Published in: Kidney international reports Vol. 2; no. 1; pp. 108 - 123
• Main Authors: Jhaveri, Kenar D, Wanchoo, Rimda, Sakhiya, Vipulbhai, Ross, Daniel W, Fishbane, Steven
• Format: Journal Article
• Language: English
• Published: United States Elsevier 01.01.2017
• Subjects: AKI; chemotherapy; hypokalemia; hyponatremia; nephrotoxicity; onconephrology; renal failure; Review; targeted therapy; targeted therapy; hypokalemia; nephrotoxicity; hyponatremia; renal failure; onconephrology; chemotherapy; AKI
• ISSN: 2468-0249; 2468-0249
• DOI: 10.1016/j.ekir.2016.09.055

Novel targeted anti-cancer therapies have resulted in improvement in patient survival compared to standard chemotherapy. Renal toxicities of targeted agents are increasingly being recognized. The incidence, severity, and pattern of renal toxicities may vary according to the respective target of the drug. Here we review the adverse renal effects associated with a selection of currently approved targeted cancer therapies, directed to EGFR, HER2, BRAF, MEK, ALK, PD1/PDL1, CTLA-4, and novel agents targeted to VEGF/R and TKIs. In summary, electrolyte disorders, renal impairment and hypertension are the most commonly reported events. Of the novel targeted agents, ipilumumab and cetuximab have the most nephrotoxic events reported. The early diagnosis and prompt recognition of these renal adverse events are essential for the general nephrologist taking care of these patients.